Meadow Creek Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Meadow Creek Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$130K	Buy	2,156 +176	+9%	+$13.1K	﹤0.01%	1146
2019 Q2	$167K	Hold	1,980	–	–	﹤0.01%	1086
2019 Q1	$189K	Hold	1,980	–	–	﹤0.01%	1037
2018 Q4	$140K	Hold	1,980	–	–	﹤0.01%	1071
2018 Q3	$169K	Buy	1,980 +616	+45%	+$61.7K	﹤0.01%	1119
2018 Q2	$158K	Hold	1,364	–	–	﹤0.01%	1065
2018 Q1	$110K	Buy	+1,364	New	+$105K	﹤0.01%	1177
2017 Q1	–	Sell	-440	Closed	-$15K	–	1303
2016 Q4	$15K	Buy	+440	New	+$12.6K	﹤0.01%	1257

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Meadow Creek Investment Management's ENTA Position: Q3 2019 in Review

Meadow Creek Investment Management increased its Enanta Pharmaceuticals (ENTA) stake by 8.9% in Q3 2019, buying an estimated $13.1K and bringing the position to 2,156 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #1146.

Meadow Creek Investment Management first reported a position in ENTA in Q4 2016 and has held it in 8 quarters since. The position peaked at $189K in Q1 2019. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

Meadow Creek Investment Management held 2,156 shares of Enanta Pharmaceuticals worth $130K as of Q3 2019.
Meadow Creek Investment Management bought 176 Enanta Pharmaceuticals shares in Q3 2019, an estimated $13.1K.
Enanta Pharmaceuticals made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1146 holding.
Meadow Creek Investment Management first reported a position in Enanta Pharmaceuticals in Q4 2016 and has held it in 8 quarters since.
Meadow Creek Investment Management's Enanta Pharmaceuticals position peaked at $189K in Q1 2019.
176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.